These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 37883691)

  • 1. Persistent Biofluid Small-Molecule Alterations Induced by
    Dean DA; Roach J; Ulrich vonBargen R; Xiong Y; Kane SS; Klechka L; Wheeler K; Jimenez Sandoval M; Lesani M; Hossain E; Katemauswa M; Schaefer M; Harris M; Barron S; Liu Z; Pan C; McCall LI
    ACS Infect Dis; 2023 Nov; 9(11):2173-2189. PubMed ID: 37883691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistent biofluid small molecule alterations induced by
    Dean DA; Roach J; vonBargen RU; Xiong Y; Kane SS; Klechka L; Wheeler K; Sandoval MJ; Lesani M; Hossain E; Katemauswa M; Schaefer M; Harris M; Barron S; Liu Z; Pan C; McCall LI
    bioRxiv; 2023 Jun; ():. PubMed ID: 37425694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Localized cardiac small molecule trajectories and persistent chemical sequelae in experimental Chagas disease.
    Liu Z; Ulrich vonBargen R; Kendricks AL; Wheeler K; Leão AC; Sankaranarayanan K; Dean DA; Kane SS; Hossain E; Pollet J; Bottazzi ME; Hotez PJ; Jones KM; McCall LI
    Nat Commun; 2023 Oct; 14(1):6769. PubMed ID: 37880260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-parasitic effect of vitamin C alone and in combination with benznidazole against Trypanosoma cruzi.
    Puente V; Demaria A; Frank FM; Batlle A; Lombardo ME
    PLoS Negl Trop Dis; 2018 Sep; 12(9):e0006764. PubMed ID: 30240395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trypanocidal drugs for late-stage, symptomatic Chagas disease (Trypanosoma cruzi infection).
    Vallejo M; Reyes PP; Martinez Garcia M; Gonzalez Garay AG
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD004102. PubMed ID: 33305846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 4-aminopyridyl-based lead compounds targeting CYP51 prevent spontaneous parasite relapse in a chronic model and improve cardiac pathology in an acute model of Trypanosoma cruzi infection.
    Calvet CM; Choi JY; Thomas D; Suzuki B; Hirata K; Lostracco-Johnson S; de Mesquita LB; Nogueira A; Meuser-Batista M; Silva TA; Siqueira-Neto JL; Roush WR; de Souza Pereira MC; McKerrow JH; Podust LM
    PLoS Negl Trop Dis; 2017 Dec; 11(12):e0006132. PubMed ID: 29281643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benznidazole treatment leads to DNA damage in Trypanosoma cruzi and the persistence of rare widely dispersed non-replicative amastigotes in mice.
    Jayawardhana S; Ward AI; Francisco AF; Lewis MD; Taylor MC; Kelly JM; Olmo F
    PLoS Pathog; 2023 Nov; 19(11):e1011627. PubMed ID: 37956215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pentamidine antagonizes the benznidazole's effect in vitro, and lacks of synergy in vivo: Implications about the polyamine transport as an anti-Trypanosoma cruzi target.
    Seguel V; Castro L; Reigada C; Cortes L; Díaz MV; Miranda MR; Pereira CA; Lapier M; Campos-Estrada C; Morello A; Kemmerling U; Maya JD; López-Muñoz R
    Exp Parasitol; 2016 Dec; 171():23-32. PubMed ID: 27729250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations.
    Garcia S; Ramos CO; Senra JF; Vilas-Boas F; Rodrigues MM; Campos-de-Carvalho AC; Ribeiro-Dos-Santos R; Soares MB
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1521-8. PubMed ID: 15793134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of nucleic acid amplification assays in monitoring treatment response in chagas disease: Usefulness in clinical trials.
    Sulleiro E; Muñoz-Calderon A; Schijman AG
    Acta Trop; 2019 Nov; 199():105120. PubMed ID: 31376368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo studies of the trypanocidal activity of a diarylthiophene diamidine against Trypanosoma cruzi.
    da Silva CF; Batista MM; Batista Dda G; de Souza EM; da Silva PB; de Oliveira GM; Meuser AS; Shareef AR; Boykin DW; Soeiro Mde N
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3307-14. PubMed ID: 18625779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experimental models in Chagas disease: a review of the methodologies applied for screening compounds against Trypanosoma cruzi.
    Fonseca-Berzal C; Arán VJ; Escario JA; Gómez-Barrio A
    Parasitol Res; 2018 Nov; 117(11):3367-3380. PubMed ID: 30232605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose benznidazole treatment results in parasite clearance and attenuates heart inflammatory reaction in an experimental model of infection with a highly virulent Trypanosoma cruzi strain.
    Cevey ÁC; Mirkin GA; Penas FN; Goren NB
    Int J Parasitol Drugs Drug Resist; 2016 Apr; 6(1):12-22. PubMed ID: 26862474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute Chagas outbreaks: molecular and biological features of Trypanosoma cruzi isolates, and clinical aspects of acute cases in Santander, Colombia.
    Díaz ML; Leal S; Mantilla JC; Molina-Berríos A; López-Muñoz R; Solari A; Escobar P; González Rugeles CI
    Parasit Vectors; 2015 Nov; 8():608. PubMed ID: 26612724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic effects of benznidazole in Swiss mice that are orally inoculated with Trypanosoma cruzi IV strains from the Western Brazilian Amazon.
    Teston APM; Fernandes NS; Abegg CP; de Abreu AP; Sarto MPM; Gomes ML; Toledo MJO
    Exp Parasitol; 2021 Sep; 228():108136. PubMed ID: 34280400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benznidazole and amiodarone combined treatment attenuates cytoskeletal damage in
    Barbosa JMC; Pedra-Rezende Y; Pereira LD; de Melo TG; Barbosa HS; Lannes-Vieira J; de Castro SL; Daliry A; Salomão K
    Front Cell Infect Microbiol; 2022; 12():975931. PubMed ID: 36093188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo antiparasitic activity of Physalis angulata L. concentrated ethanolic extract against Trypanosoma cruzi.
    Meira CS; Guimarães ET; Dos Santos JA; Moreira DR; Nogueira RC; Tomassini TC; Ribeiro IM; de Souza CV; Ribeiro Dos Santos R; Soares MB
    Phytomedicine; 2015 Oct; 22(11):969-74. PubMed ID: 26407938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological characteristics of the Trypanosoma cruzi Arequipa strain make it a good model for Chagas disease drug discovery.
    Martín-Escolano R; Rosales MJ; Marín C
    Acta Trop; 2022 Dec; 236():106679. PubMed ID: 36096184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of Benznidazole in Experimental Chronic Chagas Disease Using the Swiss Mouse-Berenice-78 Trypanosoma cruzi Strain Model.
    de Jesus SM; Pinto L; Moreira FL; Nardotto GHB; Cristofoletti R; Perin L; Fonseca KDS; Barbêdo P; Bandeira LC; Vieira PMA; Carneiro CM
    Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33168611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular and biological characterization of a highly pathogenic Trypanosoma cruzi strain isolated from a patient with congenital infection.
    Gulin JEN; Bisio M; Rocco DM; Altcheh J; Solana ME; García-Bournissen F
    Exp Parasitol; 2018 Mar; 186():50-58. PubMed ID: 29448038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.